Winter Is Coming For 2016 Biopharma Fundraising
This article was originally published in Scrip
As the Borg often stated in Star Trek's Next Generation, resistance (to a falling stock market, in this case) is futile. So, with the backdrop of a prolonged recent sell-off in pharmaceutical and biotechnology stocks that started in mid-July and which may have paused or temporarily stabilized at the time of writing, I thought that it would be instructive to explore where the sector could end up in 2016. Surprisingly, it is not all bad news.